Sort   by:  
 Page size 
UnknownOrismilast, a Potent and Selective PDE4B/D Inhibitor, Reduces Protein Levels of Key Disease Driving Cytokines in the Skin of Patients With Plaque Psoriasis.
Not available
S-EPMC12447663 | biostudies-literature
UnknownSignalling of multiple interleukin (IL)-17 family cytokines via IL-17 receptor A drives psoriasis-related inflammatory pathways.
Not available
S-EPMC8453543 | biostudies-literature
UnknownAssessing the responsiveness of sonographic biomarkers to Brodalumab therapy in Hidradenitis Suppurativa.
Not available
S-EPMC8595589 | biostudies-literature
UnknownIn-Depth Analysis of the Hidradenitis Suppurativa Serum Proteome Identifies Distinct Inflammatory Subtypes.
Not available
S-EPMC8384651 | biostudies-literature
UnknownEpithelialized tunnels are a source of inflammation in hidradenitis suppurativa.
Not available
S-EPMC8184580 | biostudies-literature
UnknownSecukinumab lowers expression of ACE2 in affected skin of patients with psoriasis.
Not available
S-EPMC7834246 | biostudies-literature
UnknownUstekinumab reduces serum protein levels associated with cardiovascular risk in psoriasis vulgaris.
Not available
S-EPMC9869081 | biostudies-literature
UnknownInterleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum.
Not available
S-EPMC9356983 | biostudies-literature
UnknownThe effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort study.
Not available
S-EPMC7572493 | biostudies-literature
UnknownAutoantigens ADAMTSL5 and LL37 are significantly upregulated in active Psoriasis and localized with keratinocytes, dendritic cells and other leukocytes.
Not available
S-EPMC6530461 | biostudies-literature
Sort   by:  
 Page size